Table 4.

Experimental autoimmune diseases suppressed by FK 506

Disorder	Species	FK 506 dose (mg/kg per day unless specified)	[Reference]
Arthritis (type II collagen-induced)	Rat (Lewis)	0.32a,b	[20]
	Rat (outbred)	2.5c	[2]
	Mouse (DBA/1)	2.0	[48]
Type-1 diabetes	NOD mouse	2.0 mg/kg per 48 ha	[32]
	Cyclophosphamide-treated NOD mouse	0.2, 1. 2	[5]
	BB rat	1.0a	[35]
	BB rat	25 μg i.m.d	[36]
Uveoretinitis	Rat (Lewis)	1.0a,e	[23]
	Rhesus & cynomolgus monkeys	0.5f	[12]
Thyroiditis	Rat (PVG)	2.0g	[49]
Lupus (SLE)	MRL/lpr/lpr mouse	2 mgh	[55]
	NZB/NZW F1 mouse	2.5 mg/kg per 48 hi	[47]
Glomerulonephritis (Nephrotoxic antiserum nephritis)	Rat (Wistar)	0.3 mgi	[15]
	Rat (Wistar)	0.64	[38]
Heymann nephritis	Rat (Wistar)	0.64a	[38]
	Rat (Lewis)	1.0k	[28]
Allergic encephalomyelitis	Rat (Lewis)	1.0j	[19]
Autoimmune myocarditis	Rat (Lewis)	0, 1 0.32, 1	[14]
Experimental allergic contact dermatitis	Farm pig	0.04, 0.4% topical	[31]
Murine (coxsackie B3) myocarditis	Mice (C3H/He)	2.5	[17]

^aSuppresses induction of disease

^bPartially effective during efferent phase of response

^cOn day of immunization

^dAdministered daily from 27–120 days of age

^eEffective only in induction phase

^fAdministered from 3 weeks after immunization

^gAdministered for 3 weeks following induction of disease

^hAdministered from 8 weeks of age

ⁱFrom time of immunization

^jAdministered 5 days per week after immunization

^kAdministered from day 0–13 or 56–69